Antibiotics in the clinical pipeline at the end of 2015
Top Cited Papers
- 29 June 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in The Journal of Antibiotics
- Vol. 70 (1), 3-24
- https://doi.org/10.1038/ja.2016.72
Abstract
There is growing global recognition that the continued emergence of multidrug-resistant bacteria poses a serious threat to human health. Action plans released by the World Health Organization and governments of the UK and USA in particular recognize that discovering new antibiotics, particularly those with new modes of action, is one essential element required to avert future catastrophic pandemics. This review lists the 30 antibiotics and two β-lactamase/β-lactam combinations first launched since 2000, and analyzes in depth seven new antibiotics and two new β-lactam/β-lactamase inhibitor combinations launched since 2013. The development status, mode of action, spectra of activity and genesis (natural product, natural product-derived, synthetic or protein/mammalian peptide) of the 37 compounds and six β-lactamase/β-lactam combinations being evaluated in clinical trials between 2013 and 2015 are discussed. Compounds discontinued from clinical development since 2013 and new antibacterial pharmacophores are also reviewed.This publication has 220 references indexed in Scilit:
- In Vitro Activities of LTX-109, a Synthetic Antimicrobial Peptide, against Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, Daptomycin-Nonsusceptible, and Linezolid-Nonsusceptible Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2012
- Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitorProceedings of the National Academy of Sciences of the United States of America, 2012
- In Vitro Activity of the New Fluoroketolide Solithromycin (CEM-101) against a Large Collection of Clinical Neisseria gonorrhoeae Isolates and International Reference Strains, Including Those with High-Level Antimicrobial Resistance: Potential Treatment Option for Gonorrhea?Antimicrobial Agents and Chemotherapy, 2012
- Substrate specificity of the deazaflavin‐dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazolesThe FEBS Journal, 2011
- In vitro activity of BAL30072 against Burkholderia pseudomalleiInternational Journal of Antimicrobial Agents, 2011
- Vancomycin and Oritavancin Have Different Modes of Action in Enterococcus faeciumJournal of Molecular Biology, 2009
- De Novo Design of Antimicrobial Polymers, Foldamers, and Small Molecules: From Discovery to Practical ApplicationsAccounts of Chemical Research, 2009
- De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamersProceedings of the National Academy of Sciences of the United States of America, 2009
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO ReleaseScience, 2008
- Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureusJournal of Molecular Biology, 2008